SR9009
Product Quick Detail
- Minimum Order
- 1
- Packaging
- N/A
- Delivery
- 3-10 Days
Specifications
SR9009 is a research drug that was developed by Professor Thomas Burris of the Scrips Research Institute as an agonist of Rev-ErbA.
SR9009 is presently under development at TSRI has been shown to considerably boost exercise endurance in animal models. Scientists think these discoveries may improvedcures for individuals suffering from illnesses that severely limit exercise endurance such as obesity, COPD (chronic obstructive pulmonary disease), congestive heart failure and also in the deterioration of muscle capacity linked with aging.
SR9009 is an easy to do oral compound can increase the level of metabolic activity in skeletal muscle of mice. The treated mice became lean, developed larger muscles and had a 50% increase in running abilities which imitates the effects of aerobic exercise.
If there is anything you wanna know , pls feel free to contact
E-mail:yana@ycphar.com
skype:yici1996
whatsapp:8618108459365
- Country:
- Business Type:
- Market:
- Founded Year:
- Address:
- Contact:yana yang
